首页|补肾活血汤治疗早发性卵巢功能不全患者的临床疗效及对其免疫因子的影响

补肾活血汤治疗早发性卵巢功能不全患者的临床疗效及对其免疫因子的影响

扫码查看
目的 探讨补肾活血汤治疗早发性卵巢功能不全(Premature ovarian insufficiency,POI)患者的临床疗效及对其免疫因子的影响.方法 选取2020年1月—2022年9月期间苏州市中医医院收治的80例POI患者,按随机数字表法分为对照组和观察组,每组各40例.对照组予常规治疗,观察组在对照组基础上加用补肾活血汤治疗.连续治疗3个月经周期,观察比较两组患者临床疗效、不良反应情况,治疗前后中医证候积分,Kupperman评分,血清促卵泡激素(Follicle-stimulating hormone,FSH)、促黄体生成激素(Luteinizing hormone,LH)、雌二醇(Estrogen,E2)水平,卵巢体积、窦卵泡数(Antral follicle count,AFC),及外周血细胞免疫(CD4+、CD8+及CD4+/CD8+)水平.结果 治疗后观察组总有效率92.5%(37/40)明显高于对照组75.0%(30/40),差异有统计学意义(P<0.05).治疗后两组患者中医证候积分及Kupperman评分均较治疗前明显降低,差异有统计学意义(P<0.05);且观察组中医证候积分及Kupperman评分均明显低于对照组,差异有统计学意义(P<0.05).治疗后两组患者血清FSH、LH水平均较治疗前明显降低,E2水平均较治疗前明显升高,差异有统计学意义(P<0.05);且观察组血清FSH、LH水平均明显低于对照组,E2水平明显高于对照组,差异有统计学意义(P<0.05).治疗后两组患者卵巢体积及AFC均较治疗前升高,差异有统计学意义(P<0.05);且观察组卵巢体积及AFC均明显高于对照组,差异有统计学意义(P<0.05).治疗后两组患者CD4+及CD4+/CD8+较治疗前升高,CD8+较治疗前降低,差异有统计学意义(P<0.05);且观察组CD4+及CD4+/CD8+高于对照组,CD8+明显低于对照组,差异有统计学意义(P<0.05).治疗期间,两组患者均未发生严重不良反应.结论 补肾活血汤能够有效减轻P0I患者临床症状,调节体内激素水平,促进卵泡发育,改善卵巢功能,提高临床疗效,其机制可能与该方能够调节POI患者机体自身免疫水平有关,且该方案具有较高安全性,值得推广.
Clinical Efficacy of Bushen Huoxue Tang on the Treatment of Premature Ovarian Insufficiency and Its Influence on Immune Factors
Objective To explore the clinical efficacy of Bushen Huoxue Tang in the treatment of patients with premature ovarian insufficiency(POI)and its influence on immune factors.Methods A total of POI 80 patients admitted to Suzhou Municipal Hospital of Traditional Chinese Medicine from January 2020 to September 2022 were selected and di-vided into a control group and an observation group according to the random number table,with 40 cases in each group.The control group received routine treatment,while the observation group received Bushen Huoxue Tang on the basis of the con-trol group.After three consecutive menstrual cycles,the clinical efficacy,adverse reactions,TCM syndrome score before and after treatment,and Kupperman score,as well as the serum levels of follicle-stimulating hormone(FSH),luteinizing hor-mone(LH),and Estrogen(E2),ovarian volume,antral follicle count(AFC),and peripheral blood cell immunity(CD4+,CD8+,and CD4+/CD8+)levels were observed and compared between the two groups.Result After treatment,the total effective rate of 92.5%(37/40)in the observation group was significantly higher than 75.0%(30/40)in the control group,and the difference was statistically significant(P<0.05).After treatment,TCM syndrome scores and Kupperman scores of the two groups were significantly reduced(P<0.05),and the TCM syndrome scores and Kupperman scores in the observation group were significantly lower than those in the control group(P<0.05).After treatment,serum FSH and LH levels in both groups were significantly decreased,and E2 levels were significantly increased(P<0.05),and the serum FSH and LH levels in the observation group were significantly lower than those in the control group,and E2 levels were sig-nificantly higher than those in the control group(P<0.05).After treatment,the ovarian volume and AFC in both groups were higher than before treatment(P<0.05),and the ovarian volume and AFC in the observation group were significantly higher than those in the control group(P<0.05).After treatment,CD4+and CD4+/CD8+were higher,and CD8+was lower(P<0.05).The CD4+and CD4+/CD8+levels in the observation group were significantly higher than those in the control group(P<0.05),while CD8+levels were significantly lower than those in the control group(P<0.05).During the treatment,neither group of patients experienced any serious adverse reactions.Conclusion Bushen Huoxue Tang can effectively alleviate the clinical symptoms of POI patients,regulate hormone levels in the body,promote follicular develop-ment,improve ovarian function,and enhance clinical efficacy.Its mechanism may be related to its ability to regulate the au-toimmune level of POI patients,and this plan is highly safe and is worth promoting.

Immune FactorsBushen Huoxue TangPremature Ovarian Insufficiency

姜薇、宋清霞

展开 >

南京中医药大学附属苏州市中医医院妇科,江苏苏州 215000

免疫因子 补肾活血汤 早发性卵巢功能不全

苏州市科技局项目

SKYD2022140

2024

世界中西医结合杂志
中华中医药学会

世界中西医结合杂志

CSTPCD
影响因子:1.053
ISSN:1673-6613
年,卷(期):2024.19(3)
  • 26